CN1209132A - 由二氧化三碳单元制成的大环化合物 - Google Patents

由二氧化三碳单元制成的大环化合物 Download PDF

Info

Publication number
CN1209132A
CN1209132A CN96180086A CN96180086A CN1209132A CN 1209132 A CN1209132 A CN 1209132A CN 96180086 A CN96180086 A CN 96180086A CN 96180086 A CN96180086 A CN 96180086A CN 1209132 A CN1209132 A CN 1209132A
Authority
CN
China
Prior art keywords
macrocyclic
com
active substance
substance according
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96180086A
Other languages
English (en)
Chinese (zh)
Inventor
F·克勒克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Donatur Dr Kerek GmbH
Original Assignee
Donatur Dr Kerek GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Donatur Dr Kerek GmbH filed Critical Donatur Dr Kerek GmbH
Publication of CN1209132A publication Critical patent/CN1209132A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
CN96180086A 1996-01-05 1996-12-30 由二氧化三碳单元制成的大环化合物 Pending CN1209132A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19600301A DE19600301C2 (de) 1996-01-05 1996-01-05 Durch Cyclooligomerisierung des einfachen Kohlensuboxids C¶3¶O¶2¶ aufgebaute makrocyclische Verbindungen, Verfahren zu deren Herstellung und Gewinnung sowie deren Verwendung
DE19600301.6 1996-01-05

Publications (1)

Publication Number Publication Date
CN1209132A true CN1209132A (zh) 1999-02-24

Family

ID=7782233

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96180086A Pending CN1209132A (zh) 1996-01-05 1996-12-30 由二氧化三碳单元制成的大环化合物

Country Status (26)

Country Link
US (1) US6187810B1 (https=)
EP (1) EP0874851B1 (https=)
JP (1) JP4195089B2 (https=)
KR (1) KR19990077000A (https=)
CN (1) CN1209132A (https=)
AR (1) AR005350A1 (https=)
AT (1) ATE233768T1 (https=)
AU (1) AU1307497A (https=)
BG (1) BG102599A (https=)
BR (1) BR9612430A (https=)
CA (1) CA2241870A1 (https=)
CZ (1) CZ208898A3 (https=)
DE (2) DE19600301C2 (https=)
EE (1) EE9800211A (https=)
ES (1) ES2194128T3 (https=)
HR (1) HRP970002A2 (https=)
HU (1) HUP9904191A2 (https=)
IL (1) IL125165A0 (https=)
JO (1) JO1945B1 (https=)
PL (1) PL327657A1 (https=)
SI (1) SI0874851T1 (https=)
SK (1) SK88598A3 (https=)
TR (1) TR199801288T2 (https=)
TW (1) TW376386B (https=)
WO (1) WO1997025333A2 (https=)
ZA (1) ZA9714B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119613750A (zh) * 2024-12-10 2025-03-14 杭州师范大学 一种机械及pH双重调控的蝶形钾离子通道分子及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO280796A0 (en) * 1996-10-07 1996-10-31 Austin Research Institute, The Methods of activating or enhancing FC receptors
DE10260537A1 (de) 2002-12-21 2004-07-15 Kerek, Franz, Dr. Peptide mit hohem Cysteingehalt
US20060067055A1 (en) * 2004-09-30 2006-03-30 Heffner Kenneth H Thermally conductive composite and uses for microelectronic packaging
WO2006039291A1 (en) * 2004-09-30 2006-04-13 Honeywell International Inc. Thermally conductive composite and uses for microelectronic packaging
CN119081077B (zh) * 2024-09-26 2025-12-26 清华大学 一种聚吡喃酮、制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119613750A (zh) * 2024-12-10 2025-03-14 杭州师范大学 一种机械及pH双重调控的蝶形钾离子通道分子及其制备方法和应用

Also Published As

Publication number Publication date
ES2194128T3 (es) 2003-11-16
JP4195089B2 (ja) 2008-12-10
TW376386B (en) 1999-12-11
KR19990077000A (ko) 1999-10-25
US6187810B1 (en) 2001-02-13
PL327657A1 (en) 1998-12-21
EP0874851B1 (en) 2003-03-05
EP0874851A2 (en) 1998-11-04
DE69626548D1 (de) 2003-04-10
JP2000503015A (ja) 2000-03-14
AU1307497A (en) 1997-08-01
WO1997025333A2 (en) 1997-07-17
DE19600301C2 (de) 1999-12-09
IL125165A0 (en) 1999-01-26
WO1997025333A3 (en) 1997-12-24
DE69626548T2 (de) 2003-12-24
CZ208898A3 (cs) 1998-10-14
AR005350A1 (es) 1999-04-28
ZA9714B (en) 1997-07-23
HUP9904191A2 (hu) 2000-05-28
BR9612430A (pt) 1999-12-28
DE19600301A1 (de) 1997-07-10
TR199801288T2 (xx) 1998-11-23
SI0874851T1 (en) 2003-10-31
JO1945B1 (en) 1997-12-15
CA2241870A1 (en) 1997-07-17
ATE233768T1 (de) 2003-03-15
HRP970002A2 (en) 1998-04-30
EE9800211A (et) 1998-12-15
BG102599A (en) 1999-03-31
SK88598A3 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
WO1994020122A1 (en) A method for treating autoimmune diseases using alpha-interferon and/or beta-interferon
JPH0770195A (ja) 糖修飾インターフェロン
CN107335049A (zh) 菊科类型环肽化合物作为cGAS‑STING信号通路抑制剂的应用
WO2015161820A1 (zh) 两亲性合成抗菌肽、其药物组合物及其用途
FI60235B (fi) Foerfarande foer framstaellning av tumoercelltillvaext inhiberande ks-2-a substans
CN1649610A (zh) 一种用于加强温血动物的免疫、抗炎、抗肿瘤以及 d n a修复过程的植物水溶性提取物生物活性组分的分离纯化以及结构鉴定
WO2000009137A2 (en) Aminosterol compounds and uses thereof
CN1209132A (zh) 由二氧化三碳单元制成的大环化合物
US5759550A (en) Method for suppressing xenograft rejection
JP2548822B2 (ja) マカラスムギ由来の糖タンパク質、その製造法及びそれを含有する免疫調節剤
WO1995013082A1 (en) Immunotherapy composition and method
RS49733B (sr) Soli bpc peptida sa organo- zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena
CN101161674A (zh) 一种环肽,其制备方法和其应用
CN1602200A (zh) 具有免疫刺激剂活性的植物提取物
JP3673304B2 (ja) 新規創傷治癒物質
EP1968575B1 (en) Immunomodulatory pharmaceutical composition containing a combination of three coumarinolignoids
US5656601A (en) Acylated splenopentins, methods for their synthesis and their use
JP2000103789A (ja) プロポリス由来のベンゾピラン誘導体の生理活性
WO2003007874A2 (en) Anti-tumor activity from reptile serum
CN119119208A (zh) Buforin llb或其衍生肽作为ARF6抑制剂及应用
JP3117985B2 (ja) 細菌性ショック治療剤
CN120230092A (zh) 具有抗弓形虫活性的吲哚苯乙烯基噁二唑桥联体化合物
TWI355933B (en) Andrographolide and its derivatives as tnf-α antag
JPH0692867A (ja) 免疫系賦活剤
JPH02184699A (ja) “８−アミノ酸”に改良のある新規シクロスポリン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication